Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating valbenazine as an adjunctive treatment for schizophrenia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INGREZZA (valbenazine)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED